Oncolytics Biotech Inc T.ONC

ONCY has just added to the profit margin of Cantor Fitzgeral

[JohnnyYeg]

$50 million equity distribution deal just dropped - the day after the Q2 call.

[Azzak34]

Shelf offering. May not dilute the whole lot or any at all. Realistically there'll be some more dilution until we've got all the ducks lined up so it is to be expected.  Not a big deal. So if we need the money it's available to us, if we don't there'll be no dilution.  Much more more positive sign than a straight atm. 

[jh1970]

Where is this news ? Can you give a link ?

[JohnnyYeg]

https://oncolyticsbiotech.com/investor-overview/filings/ SEC filings and the latest 6K posted today

[Noteable]

On August 2, 2024, Oncolytics Biotech Inc. (the “Registrant”) entered into an at-the-market sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., pursuant to which the Registrant may, at its discretion, from time to time, sell up to $50-million worth of common shares.   On July 12, 2024, the Registrant terminated its equity distribution agreement dated June 17, 2022

[Noteable]

I would think that who've been using Canaccord to trade the stock expecting to cover through the now terminated ATM with  Canaccord, are in for a big surprise.

[Noteable]

Should read:  I think that those who've been using Canaccord...

[Noteable]

The average estimated total cost for all "per patient'' activities of a clinical trial with new anticancer agents was 11,379 Euros / US$12,421 per patient using the activity-based costing (ABC) methodology. Pivotal (phase 3) studies for new drugs that were subsequently approved by the U.S. Food and Drug Administration (FDA) cost a median of $41,117 per patient.

[Noteable]

Throws open the door to the Accelerated Approval pathway for ONCY's pelareorep in combination with paclitaxel for the treatment of HR+/HER2- metastatic Breast Cancer used in 2 different scenarios- (1) either prior to (in ADC intolerant) which was originally planned before ADC therapy, or (2) following ADC therapy (in ADC failure). 

[Noteable]

The Cantor Fitzgerald ATM replaces the Canaccord arrangement and has been discussed here. The Cantor ATM throws open the door to the Accelerated Approval pathway for ONCY's pelareorep in combination with paclitaxel for the treatment of HR+/HER2- metastatic Breast Cancer used in 2 different scenarios- (1) either prior to (in ADC intolerant) which was originally planned before ADC therapy, or

[Noteable]

The Cantor Fitzgerald ATM replaces the Canaccord arrangement and has been discussed here. Below is the notification from the SEC filing. "On August 2, 2024, Oncolytics Biotech Inc. (the “Registrant”) entered into an at-the-market sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., pursuant to which the Registrant may, at its discretion, from time to time, sell up to $50